- Home
- FTFT vs MBRX Comparison
FTFT vs MBRX Comparison
Compare FTFT & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FTFT | MBRX |
|---|---|---|
| Founded | N/A | 2015 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2M | 6.1M |
| IPO Year | 2008 | 2016 |
Fundamental Metrics
Financial Performance| Metric | FTFT | MBRX |
|---|---|---|
| Price | $1.16 | $2.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $61.00 |
| AVG Volume (30 Days) | 10.1K | ★ 108.6K |
| Earning Date | 05-19-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,829,805.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 77.46 | N/A |
| 52 Week Low | $0.56 | $0.25 |
| 52 Week High | $4.03 | $7.98 |
Technical Indicators
Market Signals| Indicator | FTFT | MBRX |
|---|---|---|
| Relative Strength Index (RSI) | 37.33 | 45.74 |
| Support Level | $1.02 | $0.37 |
| Resistance Level | $1.32 | $2.52 |
| Average True Range (ATR) | 0.11 | 0.14 |
| MACD | -0.00 | 0.08 |
| Stochastic Oscillator | 11.98 | 63.64 |
Price Performance
Historical ComparisonAbout FTFT Future FinTech Group Inc.
Future FinTech Group Inc is engaged in the financial technology business. The company participates in supply chain financing services and trading in China, asset management business in Hong Kong, and cross-border money transfer services in the United Kingdom. It has also expanded into brokerage and investment banking business in Hong Kong and a cryptocurrency mining farm in the U.S. The company's reportable segments include asset management services, supply chain financing and trading, and others.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.